TruScreen Group (ASX:TRU, NZE:TRU) said that a July 2024 Saudi Arabia study investigating the TruScreen cervical screening technology's performance versus pap smears in cervical cancer detection was peer reviewed and published by the BMC Women's Health journal, according to bourse filings in Australia and New Zealand on Thursday.
The study tested 507 women and reported that Truscreen demonstrated a high sensitivity of 83.3%, compared to 66.7% from pap smears, and a high specificity of 95%, compared with 98.2% from pap smears, the filing said.